In C26 tumor-bearing mice, treatment with or without Folfiri (a chemotherapeutic agent) causes muscle atrophy and reduces the expression of mitochondrial fusion markers (OPA1 and Mfn2), fission markers (Drp1), and biogenesis markers (PGC-1α) in muscle cells. The gene discussed is DNM1L; the disease is neoplasm.